DiponEd: Transforming Treatments to Personalized Cure

Healthcare in today’s time has become crucial in terms of accessibility and ease of facilitation. As new diseases are emerging from the nooks and corners of the world, the medical industry with all its dynamism needs to double down to counter such diseases in an effective and efficient manner.

Moreover, to target the specific diseases while diminishing or eliminating its effects, the advent of precision medicine is moving from a niche to a widely accepted method for treatments. Also known as personalized medicine, it is moving closer to be precise, predictable and powerful healthcare approach which can be customized for any individual patient.

Even the world’s best doctors and scientists don’t completely comprehend the development of different diseases in people and their response to the respective treatments. The ‘one-size-fits-all’ approach to medicine has been implemented by lots of medical and healthcare providers which is based on broad population averages. The traditional practices often misses its mark as each person’s genetic makeup is quite different from other people. This very often, can affect the health of an individual in important ways.

The growing understanding of genetics and genomics is enabling the doctors to provide better disease prevention, accurate diagnosis, safer drug prescriptions and effective treatments for many people. Personalized medicine is playing a vital role in tailoring healthcare to every person’s unique genetic makeup. That is the promising idea behind precision/personalized medicine. This approach towards the healthcare services has revolutionized how the medical industry works and have facilitated results that are quintessential for individual patient’s overall development.

DiponEd BioIntelligence is an organization working with such an approach in the Indian healthcare domain. It is an innovative healthcare biotechnology company driven by strong in-house R&D. It offers precision and personalized medicine products, services, and solutions meeting global standards. The company is developing a point of care biological devices for isolation of stem cells, PRP, Biologicals, Biosimilars, Neo Antigens, and Cellular therapies. These therapies include Mesenchymal Stem Cells, NK Cell & T cell for cancer, autoimmunity, diabetes, neurological problems, orthopedics, infertility, cardiovascular disease, diabetes, anti-aging, and dermatology, etc.“We focus on developing the next-generation bio-intelligent products to address unmet healthcare needs,” says the team of DiponEd.
More about DiponEd
DiponEd has also developed a range of personalized diagnostics and prognostic tests like liquid biopsies, gut metagenomics, pesticide tolerance, genetic predispositions, stress scoring, 3D printed orthotics- prosthetics – modeling, drug overloads, omics of diseases, etc. under its brand Merisis Therapeutics. DiponEd Institute of Regenerative Medicine has been offering education in regenerative medications to clinicians through its hybrid online and hands-on training programs.

The company was started in 2010 with an idea to develop solutions and treatments for unmet medical needs like cancer, nonhealing wounds, burns, muscular dystrophies, autoimmune conditions like rheumatoid arthritis and T1 diabetes, and several other debilitating conditions like ALS, MS, COPD, ILD, T2 diabetes, etc. The team at DiponEd soon realized that prevention is better than cure for most of these above-mentioned conditions. Though, integration of preventive, predictive, participatory, and personalized medicine is required to reach from ‘treatment to cure’. This could prove to be a major diversion for current health care treatment business models.

“We then started working on developing products and services like predictive and prognostic genetic and molecular tests for suspects or patients, and also personalized therapeutics,” states DiponEd’s team. The company is currently integrating many in-house technologies as well as some foreign service providers to make an entire ecosystem to develop a personalized cure for various diseases.

DiponEd-CRS (Contract Research Services) is a wing of the company, providing an R&D ecosystem with a team of highly experienced and qualified scientists. The wing acts as a supporting facility for many international Bio-Pharma companies. This division offers its services in the domains of integrated drug discovery of small molecules in the areas of in-silico modeling, PK-PD modeling, and system biology. These services also facilitate ADME, toxicology, pre-clinical optimization, in vitro biology and (Enzyme assays, Cell-based assays, Ligand binding assays, GPCR, ELISA) in vivo biology, etc. DiponEd also provides services in the domain of Molecular biology, immunogenicity assays, formulation development and Regulatory Assistance for the Indian FDA. DiponEd CRS is an official empanelled partner to Andhra Pradesh Medical Tech Zone (AMTZ), Kalam Institute of Health Technology, for medical devices and regulatory support.

Versatile Offerings, Simplified Services

The power of biotechnology and biomedical engineering has helped the company’s R&D team to design multiple programs targeting cellular biologicals, stem cell transplantation & processing protocols, developing monoclonal antibodies (MAbs) and cellular therapies. “We design and create biomaterials using our proprietary 3D printing technology and 3D tissue engineering,” states the team of DiponEd.

The company’s focus is on current personalized medicine which includes genetic predispositions, mutation detection, cancer-integrated therapies, pharmacogenomics-based drug response tests, anti-aging, stem cells transplantations in blood-related disorders, biomaterials, 3D reconstructions, orthotics, radiation, chemoprotection, personalization, skin and hair treatments, infertility and healthcare products.

DiponEd provides new devices and technologies along with the solutions which are developed in-house and are at feasible costs, usually at a fraction of the costs from the US or Chinese. The firm is also integrating all the services under one roof to emerge as a one-stop solution provider for personalized medicine services. The company is also contributing towards the corporate social responsibility cause through its primary health care initiatives at rural/semi-rural townships. Especially, in the areas of diabetic foot ulcers and pain management curated for the unprivileged section of the society.

Remarkable Footprints

DiponEd emerged as Elevate 100 Award Winner, 2017. It was also selected as the Emerging Leader in the Medical Devices industry in India, for Merisis Therapeutics point of care kits presented at THE HEALTHCARE-PHARMA & MEDICAL DEVICES SUMMIT & EXCELLENCE AWARDS 2017 on 4th August 2017 at St. Regis, Mumbai. The firm received Karnataka State’s quality leadership award, by the World Quality Congress & Awards in 2019.
Under the leadership of Dr. Kaushik Deb, Founder, CEO, and Managing Director of DiponEd – the company has developed more than 30 patented products and services. It is collaborating with more than 20 international and National labs and education institutions to develop its unique line of therapeutics. He also established the DiponEd Institute of Regenerative Medicine (DIRM), offering Certificate Course in Regenerative Medicine (CCRM) and Fellow Program in Regenerative Clinical Medicine (FRCM) with the DDM university.

He is the Director of Indian association of laser therapies (IALT), and Secretary, Society of Tissue Engineering and Regenerative Medicine (India). He has done M.Sc, MD (IM), Ph.D., Post Doc Associate (USA, Canada), EGMP (IIM-B) and FRHS. He has been awarded the Govt of India DBT’s, Overseas Bilateral exchange Associateship with Ottawa General Hospital, and the Indian National Academy of Sciences (INSA)- bilateral exchange award with the Czech Science Academy. He has published over 70 peer-reviewed research papers, abstracts, and book chapters, and is also an active reviewer for 4 international journals and editorial board member for 5 international journals. He has authored the book entitled ‘Stem Cells; Basic and Applications’ published by McGraw Hill New Delhi and ‘Stem cell Technologies’ by McGraw Hill, New Jersey, USA. Dr. Kaushik has developed/ patented platform technologies for personal health care and personalized therapies in cancer, radiation, hair and skin regeneration, Oestochondral defects, organ-specific aging, age-associated conditions, diabetics AMR, 3D tissue engineering, etc.

Dr. Kaushik has been awarded the Govt of India DBT’s, Overseas Bilateral exchange Associateship with Ottawa General Hospital, and the Indian National Academy of Sciences (INSA)- bilateral exchange award with the Czech Science Academy. He has also been honored with MED ACHIEVERS ICON AWARD for his work in the field of Healthcare. He and his team are developing 3D bioprinting and 3D printing services, under the ‘Uchhattar Avishkar Yojana’ award, supported by the Ministry of Health Government of India.

DiponEd is setting up novel Artificial intelligence platforms P4M Cure Clinic and apps,  and new algorithms are being derived to learn about healthcare and diseases. All of this while creating integrated clinical data for Predictive, Preventive, Participatory and Personalized medicine, in collaboration with hospitals globally. The R&D team is working on several unique aspects of modern health care challenges like Drug interactions in patients, Drug overloads, Chemosensitivity, Liquid biopsies, Genomics, Proteomics, Metabolomics, Molecular and Genetic diagnostics, and Prognostics, cellular biological APIs, therapeutic devices (Merisis Therapeutics). It is also creating other personalized products in cancer, nephrology, podiatry, DFUs, burns, sports injuries, orthopedics, dermatology, etc.

“We are a bio-intelligent solutions company with a focus on unique formulations and solutions. All our health care products are derived out of in house R&D using data mining, lab tests, artificial intelligence applications, and advanced biotechnology. We strive to be faster, better and cheaper from any other products and services company,” concludes Dr. Kaushik.